Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | Thalassemia Therapeutics - Pipeline Assessment and Market Forecasts to 2018The Thalasssemia Therapeutics Market is Forecast to Grow Up Until 2018
By: Rajesh Gunnam GlobalData has estimated the thalassemia therapeutics market has significant unmet need. The currently marketed drugs - iron chelating drugs that are used to treat iron overload arising from blood transfusions - do meet patient needs to a satisfactory extent. However, there is no cure for the disease through the drugs that are currently available and this remains a significant unmet need in the thalassemia therapeutics market. The need for safer and more efficacious drugs is also another unmet need. Also, the cumbersome routes of administration and dosing regimens have a negative effect on clinical outcomes.With no new molecule expected to hit the market until almost the end of the forecast period, the clinical unmet need is likely to remain unaltered over the next few years. The competition in the thalassemia therapeutics market will remain strong in the future. The current market is strong as there are three approved drugs that are available to thalassemic patients suffering from iron overload arising from blood transfusions. These are Desferal, Ferriprox, and Exjade, and these are widely prescribed. New drug launches are not expected untill 2017, and it is unlikely that these three drugs will see any stiff competition in the immediate future. For Sample Pages, please click or add the below link to your browser: http://www.globaldata.com/ It is GlobalData’s estimate that the impact of the uptake of these three new entrants on the fortunes of the already established drugs will be minimal during the forecast period. GlobalData’s analysis shows that the thalassemia developmental pipeline is weak, with only eight molecules in the pipeline. Though all of them are first-in-class (FIC) molecules, thereby holding out the promise of driving the market up, it has to be noted that they are all in the very early stages of development. This implies that the thalassemia developmental pipeline is likely to continue to be weak, although the three Phase II molecules that might hit the market towards the end of the forecast period are promising. GlobalData, the industry analysis specialist, has released its new report, “Thalassemia Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Thalassemia Therapeutics market. The report identifies the key trends shaping and driving the global Thalassemia Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Thalassemia Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. For further details, please click or add the below link to your browser: http://www.globaldata.com/ Visit our report store: http://www.globaldata.com/ For more details contact: pressreleases@ North America: +1 646 395 5477 Europe: Asia Pacific: # # # GlobalData is a global market intelligence services company providing information research and analysis products and services. End
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Account Phone Number